Enteroporc Coli AC

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

CLOSTRIDIUM PERFRINGENS TYPE C, BETA1 TOXOID / Clostridium perfringens, type A, alpha toxoid / Clostridium perfringens, type A, beta2 toxoid / Escherichia coli, fimbrial adhesin F4ab / Escherichia coli, fimbrial adhesin F4ac / Escherichia coli, fimbrial adhesin F5 / Escherichia coli, fimbrial adhesin F6

Available from:

CEVA Santé Animale

ATC code:

QI09AB08

INN (International Name):

Neonatal piglet colibacillosis (recombinant, inactivated), Clostridium perfringens vaccine (inactivated)

Therapeutic group:

Prašiči

Therapeutic area:

Immunologicals for suidae, Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium

Therapeutic indications:

For the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           Clinical signs (severe diarrhoea) and mortality caused by Escherichia coli strains expressing the fimbrial adhesins F4ab, F4ac, F5 and F6-           Clinical signs (diarrhoea during the first days of life) associated with Clostridium perfringens type A expressing alpha and beta 2 toxins-           Clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by Clostridium perfringens type C expressing beta1 toxin.

Product summary:

Revision: 1

Authorization status:

Pooblaščeni

Authorization date:

2020-12-09

Patient Information leaflet

                                15
B. NAVODILO ZA UPORABO
16
NAVODILO ZA UPORABO
ENTEROPORC COLI AC LIOFILIZAT IN SUSPENZIJA ZA SUSPENZIJO ZA
INJICIRANJE ZA PRAŠIČE
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ, ČE STA
RAZLIČNA
Imetnik dovoljenja za promet z zdravilom:
Ceva Santé Animale
10 av. de La Ballastière
33500 Libourne
Francija
Proizvajalec odgovoren za sproščanje serij:
IDT Biologika GmbH
Am Pharmapark
06861 Dessau-Rosslau
Nemčija
Ceva-Phylaxia Veterinary Biologicals Co. Ltd.
Szállás u. 5.
1107 Budapest
Madžarska
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Enteroporc COLI AC liofilizat in suspenzija za suspenzijo za
injiciranje za prašiče
3.
NAVEDBA UČINKOVIN(E) IN DRUGE(IH) SESTAVIN
En odmerek (2 ml) vsebuje:
UČINKOVINE:
LIOFILIZAT:
toksoidi bakterije
_Clostridium perfringens_
tipa A/C:
toksoid alfa
≥ 125 rE/ml*
toksoid beta1
≥ 3354 rE/ml*
toksoid beta2
≥ 794 rE/ml*
SUSPENZIJA:
inaktivirani fimbrijski adhezini bakterije
_Escherichia coli_
:
F4ab
≥ 23 rE/ml*
F4ac
≥ 19 rE/ml*
F5
≥ 13 rE/ml*
F6
≥ 37 rE/ml*
* Vsebnost toksoidov in fimbrijskih adhezinov v relativnih enotah na
mililiter, določena s testom ELISA glede
na interni standard.
DODATEK:
aluminij (v obliki hidroksida)
2,0 mg/ml
17
Bež do rjav liofilizat.
Rumenkasta suspenzija.
4.
INDIKACIJE
Za pasivno imunizacijo potomcev z aktivno imunizacijo brejih svinj in
mladic za zmanjšanje:
-
kliničnih znakov (hude driske) in pogina, ki jih povzročajo sevi
bakterije
_E. coli_
, ki izločajo
adhezine F4ab, F4ac, F5 in F6;
-
kliničnih znakov (driske) v prvih dnevih po prasitvi, povezanih z
bakterijo
_Clostridium _
_perfringens_
tipa A, ki izloča toksina alfa in beta2;
-
kliničnih znakov in pogina, povezanih s hemoragičnim in
nekrotizirajočim enteritisom, ki ga
povzroča bakterija
_Clostridium perfringens_
tipa C, ki izloča toksin beta1.
Nastop imunosti (po zaužitju kolostruma):
_E. coli_
F4ab, F4ac, F5, F6: v 12 urah po prasitvi
_C. perfringens_
tipa A in C: 1. dan po prasit
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 24-09-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 24-09-2021
Public Assessment Report Public Assessment Report Bulgarian 20-08-2021
Patient Information leaflet Patient Information leaflet Spanish 24-09-2021
Public Assessment Report Public Assessment Report Spanish 20-08-2021
Patient Information leaflet Patient Information leaflet Czech 24-09-2021
Public Assessment Report Public Assessment Report Czech 20-08-2021
Patient Information leaflet Patient Information leaflet Danish 24-09-2021
Public Assessment Report Public Assessment Report Danish 20-08-2021
Patient Information leaflet Patient Information leaflet German 24-09-2021
Public Assessment Report Public Assessment Report German 20-08-2021
Patient Information leaflet Patient Information leaflet Estonian 24-09-2021
Public Assessment Report Public Assessment Report Estonian 20-08-2021
Patient Information leaflet Patient Information leaflet Greek 24-09-2021
Public Assessment Report Public Assessment Report Greek 20-08-2021
Patient Information leaflet Patient Information leaflet English 24-09-2021
Public Assessment Report Public Assessment Report English 20-08-2021
Patient Information leaflet Patient Information leaflet French 24-09-2021
Public Assessment Report Public Assessment Report French 20-08-2021
Patient Information leaflet Patient Information leaflet Italian 24-09-2021
Public Assessment Report Public Assessment Report Italian 20-08-2021
Patient Information leaflet Patient Information leaflet Latvian 24-09-2021
Public Assessment Report Public Assessment Report Latvian 20-08-2021
Patient Information leaflet Patient Information leaflet Lithuanian 24-09-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 24-09-2021
Public Assessment Report Public Assessment Report Lithuanian 20-08-2021
Patient Information leaflet Patient Information leaflet Hungarian 24-09-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 24-09-2021
Public Assessment Report Public Assessment Report Hungarian 20-08-2021
Patient Information leaflet Patient Information leaflet Maltese 24-09-2021
Public Assessment Report Public Assessment Report Maltese 20-08-2021
Patient Information leaflet Patient Information leaflet Dutch 24-09-2021
Public Assessment Report Public Assessment Report Dutch 20-08-2021
Patient Information leaflet Patient Information leaflet Polish 24-09-2021
Public Assessment Report Public Assessment Report Polish 20-08-2021
Patient Information leaflet Patient Information leaflet Portuguese 24-09-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 24-09-2021
Public Assessment Report Public Assessment Report Portuguese 20-08-2021
Patient Information leaflet Patient Information leaflet Romanian 24-09-2021
Public Assessment Report Public Assessment Report Romanian 20-08-2021
Patient Information leaflet Patient Information leaflet Slovak 24-09-2021
Public Assessment Report Public Assessment Report Slovak 20-08-2021
Patient Information leaflet Patient Information leaflet Finnish 24-09-2021
Public Assessment Report Public Assessment Report Finnish 20-08-2021
Patient Information leaflet Patient Information leaflet Swedish 24-09-2021
Public Assessment Report Public Assessment Report Swedish 20-08-2021
Patient Information leaflet Patient Information leaflet Norwegian 24-09-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 24-09-2021
Patient Information leaflet Patient Information leaflet Icelandic 24-09-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 24-09-2021
Patient Information leaflet Patient Information leaflet Croatian 24-09-2021
Public Assessment Report Public Assessment Report Croatian 20-08-2021